Bal Pharma Approves FY26 Results, Recommends ₹1.20 Dividend

Bal Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹1.20 per equity share, subject to shareholder approval. They also appointed Murugesh & Co as Internal Auditors and G.N.V & Associates as Cost Auditors for FY26. Additionally, the board approved granting 5,00,000 stock options to employees and a preferential issue of 10,00,000 warrants to promoters. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer.